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Abstract 33 
Purpose: To study UK practice patterns for the management of retinal detachment secondary 34 
to macular hole (MHRD) and macular retinoschisis (MRS) in pathological myopia (PM). To 35 
review the anatomical and visual outcomes of the surgically managed cases. 36 
Methodology: A prospective observational case series for the management of MHRD was 37 
undertaken in association with the British Ophthalmological Surveillance Unit (BOSU). The 38 
results were combined with retrospective data, collected by the COllaboration of British RetinAl 39 
Surgeons (COBRA), on the management of both MHRD and MRS in PM in the UK. A total of 20 40 
cases of MHRD and 53 cases of MRS (27 surgical cases and 26 cases managed conservatively) 41 
are reported in this combined study.  42 
Results: 43 
MHRD: Mean baseline best corrected visual acuity (BCVA) was 1.60 logMAR. All cases 44 
underwent pars plana vitrectomy (PPV). Mean post-operative BCVA was 1.49 logMAR 45 
(p=0.674). The macular hole was closed in 5/20 (25%) cases, open/flat in 10/20 (50%) cases 46 
and open/elevated in 4/20 cases (20%).  47 
MRS: Mean baseline BCVA was 0.87 logMAR in the surgical group and 0.45 logMAR in the 48 
conservatively managed group (p=0.002). All eyes that had surgical intervention underwent 49 
PPV. Mean post-operative BCVA was 0.68 logMAR (p=0.183). Anatomical outcomes 50 
demonstrated a persistent MRS in 2/27 (7.4%) cases, partial resolution in 7/27 (25.9%) cases 51 
and complete resolution in 16/27 (59.2%) cases.  52 
Conclusions: PPV is the only surgical procedure performed for the management of MHRD 53 
and MRS amongst the study participants. Success rates and visual outcomes are limited for 54 
MHRD and consistent with the current literature for MRS.  55 
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INTRODUCTION 56 
Pathogenesis 57 
Pathological myopia (PM) is a common cause of visual loss worldwide and the global 58 
prevalence appears to be increasing particularly in Asian populations.1,2 Prevalence estimates 59 
have been difficult to ascertain due to varying study definitions and differences between 60 
populations. The estimated prevalence in the USA, Western Europe and Australia is 2.8-61 
4.6%.1,2 The definition of PM has been recently updated and is defined as eyes with 62 
characteristic myopic fundal findings and a refractive error of ≥-8 Dioptres.3,4 63 
Amongst the spectrum of complications associated with PM, macular hole with secondary 64 
retinal detachment (MHRD) and macular retinoschisis (MRS) have been difficult to manage.5,6 65 
While the exact pathogenesis of MHRD is unknown many hypotheses have been suggested 66 
including anterior-posterior vitreoretinal tractional forces, posterior staphyloma and large areas 67 
of chorioretinal atrophy leading to weak adhesion between the retina and the underlying retinal 68 
pigment epithelium (RPE).7-9 69 
In 1999, Akibi et al. were the first to report the role of staphyloma in contributing to retinal 70 
detachment in the presence of macular hole rather than anterio-posterior vitreomacular 71 
traction.10 During a similar period Takano et al also found that retinal detachment and MRS 72 
were common features in high myopes with staphyloma but postulated that retinal detachment 73 
may precede macular hole formation.11 With increasing age, the incidence and size of the 74 
staphyloma increase. This may be associated with progressive stretching and thinning of the 75 
retina because of the disparity between the retina and the sclera, which could precipitate the 76 
development of retinal detachment or retinoschisis.12  77 
High resolution optical coherence topography (OCT) provides a detailed examination of the 78 
retinal structure and allows the distinction between macular detachment and retinoschisis.13 79 
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MRS in PM is now considered a progressive condition leading to macular hole and secondary 80 
retinal detachment when myopic traction maculopathy is present, with high rates of 81 
progression in cases of extensive macular retinoschisis.14-23 It would therefore appear that both 82 
intraocular and outer ocular wall factors can impact on the natural progression to MHRD and 83 
the outcome of treatment strategies. 84 
The treatment criteria and management of MHRD and MRS also remains controversial.6 Pars 85 
plana vitrectomy (PPV), encircling scleral buckle, peeling of ILM/pre-retinal membranes, 86 
various intraocular tamponade agents and macular buckle have all been used with variable 87 
success rates. Traditionally, the management in the UK has involved PPV, ERM/ILM peel 88 
with gas or oil tamponade.24 While macular buckling for MHRD was originally developed to 89 
treat the posterior staphyloma, further interest in this technique has increased during the last 90 
10-15 years at least in part because of the limited success rates with vitrectomy alone.5,25-28   91 
The aim of this study is to gain an understanding of the UK practice patterns for the 92 
management of retinal detachment secondary to macular hole (MHRD) and macular 93 
retinoschisis (MRS) in pathological myopia (PM). The study also aims to review the 94 
anatomical and visual outcomes of the surgical management of these cases. 95 
METHODS 96 
A prospective observational case series for the management of MHRD was carried out in 97 
association with the British Ophthalmological Surveillance Unit (BOSU). BOSU data were 98 
combined with data from a retrospective Collaboration of British RetinAl Surgeons (COBRA) 99 
data provided by a group of UK vitreoretinal surgeons. Retrospective COBRA data included cases 100 
of MHRD that had been managed surgically in addition to cases of MRS, which had either 101 
undergone surgical or conservative management.  102 
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Initial case ascertainment was through the BOSU reporting system from October 2013-October 103 
2014 in collaboration with the Royal College of Ophthalmologists and covered Britain and 104 
Northern Ireland. The retrospective COBRA data was based on consecutive cases collected by 105 
a group of 9 British Vitreoretinal surgeons from April 2011- April 2016. A standardised 106 
questionnaire had been designed and approved by the BOSU steering group after refinement by 107 
interested Ophthalmologists.  108 
 109 
BOSU provides an established infrastructure to prospectively investigate ophthalmic 110 
conditions with important public health implications in the UK. All Consultant 111 
Ophthalmologists in the UK were sent a monthly report card to report any case of myopia 112 
associated MHRD during the surveillance period. The case definition was as noted in the 113 
methods section of the present paper.   The BOSU questionnaire was sent to all reporting UK 114 
Ophthalmologists immediately on receiving notification from the BOSU team and a further 115 
follow-up questionnaire was sent 6 months later. The same initial and follow up questionnaires 116 
were utilised in the retrospective COBRA study and sent to the study participants.  Case 117 
definition and completeness of response was validated by the principle contact at the point of 118 
data entry; reporting ophthalmologists were contacted for further information as necessary. The 119 
questionnaire included details on the following variables and potential confounders: age, gender, 120 
lens status, axial length, macular pathology, surgical procedures, endotamponade utilised, 121 
posturing regime, baseline best corrected visual acuity (BCVA) and post-operative visual and 122 
anatomical outcomes in the cases that were surgically managed.  123 
 124 
Visual acuity data were reported in either Snellen acuity or logMar units and where necessary 125 
converted to logMar equivalent. Data were analysed using Stata 14.1 (StataCorp LP) software. 126 
Analyses were performed with the Pearson X2 test, student’s t-test and analysis of variance 127 
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(ANOVA). A p-value of <0.05 was taken as statistically significant. Only those variables 128 
showing significant associations on univariate analysis were included in the multivariate 129 
models. 130 
 131 
Case definitions: At the time of the current study the definition of PM was widely accepted as a 132 
spherical equivalent refractive error of ≥-6 Dioptres or an axial length of ≥25.5 mm with 133 
characteristic degenerative changes.3 While this has been updated more recently to eyes with 134 
characteristic myopic fundal findings and a refractive error of ≥-8 Dioptres, the former 135 
definition of PM has been used for both the BOSU data and the COBRA data.4 136 
We included all cases of MHRD, which was defined as the separation of the sensory retina 137 
from the RPE by subretinal fluid (SRF) extending at least as far as the edge of the temporal 138 
retinal vasculature around the macula where the macular hole is the primary break that resulted 139 
in retinal detachment. The presence of retinal detachment was confirmed using OCT. The 140 
postoperative anatomic outcome was based on the macular hole appearance using OCT at six 141 
months where the macular hole appearance is defined as open/flat, open/elevated or closed. 142 
Retinal reattachment based on OCT at six months is defined as attachment of the retina without 143 
any tamponade present and no subretinal fluid present, which could spread. This would include 144 
eyes with anterior fluid walled off by 360-degree retinopexy. 145 
We included all cases with MRS based on the OCT appearance, which was defined as splitting 146 
of the inner or outer plexiform layers of the retina. The postoperative anatomic outcome was 147 
based on the OCT appearance of the MRS at six months, based on the complete or partial 148 
resolution of the retinoschisis.  149 
Patients with peripheral retinal breaks and a peripheral retinal detachment at presentation were 150 
excluded from the study. 151 
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The study obtained ethical approval from Whipps Cross University Hospital, Barts Health 152 
NHS Trust ethics committee and adhered to the tenets of the Declaration of Helsinki. The 153 
study used non-identifiable data collected during the course of routine clinical practice. 154 
RESULTS 155 
Macular Hole Retinal Detachment 156 
A total of 20 cases of MHRD were identified. Ten cases were recruited from the prospective 157 
study and 10 cases were recruited from the retrospective study. The mean age of participants at 158 
baseline was 63.9 years (range from 37-83 years) and included 14 (70%) female participants. 159 
Baseline characteristics included a mean pre-operatively BCVA of 1.60 logMAR (range: 0.2-160 
3.0) with an axial length of 25.5-30.0mm in 10/20 cases and > 30.0mm in 9/20 cases (1 case 161 
not specified). The duration of central visual loss was < 1 week in 3 cases, 1-4 weeks in 4 cases 162 
and > 4 weeks in 13 cases. Baseline macular status is highlighted in table 1 (data was missing 163 
for 1 case) and demonstrates a high proportion with posterior staphyloma (16/19 cases) and 164 
macular retinoschisis (9/19 cases).  165 
All cases were managed by PPV with gas or oil tamponade as demonstrated in table 1. The 166 
most frequently stated endotamponade used was C2F6 in 9/20 (45%) cases and drainage of the 167 
subretinal fluid through the macular hole was carried out in 16/20 (80%) cases. Posturing 168 
regimes varied but the most frequently stated posturing regime was for 1-7 days in 11/20 169 
(55%) cases. 170 
Mean follow-up was for a period of 6.3 months (range: 6-12 months) and BCVA remained 171 
stable with a mean of 1.60 logMAR at baseline and a mean of  1.49 logMAR (range: 0.4-3.0) 172 
post-operatively (p=0.674). BCVA decreased post operatively in 5/20 (25%) cases, was 173 
unchanged in 3/20 (15%) cases and improved in 12/20 (60%) cases. A total of 8/20 (40%) 174 
cases improved by >0.30 logMAR units or 2 Snellen lines (figure 1). Older age was associated 175 
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with improved BCVA on univariate analysis (p=0.039) and the use of C2F6 had a borderline 176 
association with improved BCVA (p=0.05). However, these variables were no longer 177 
significantly associated when carried through to multivariate analysis. 178 
The macular hole was reported as closed in 5/20 (25%) cases, open and flat in 10/20 (50%) 179 
cases and open and elevated in 4/20 (20%) cases (with 1 case undetermined due to difficulty in 180 
interpreting the OCT findings). The presence of MRS was significantly associated with an 181 
open/elevated MH (p=0.024). A post-operatively open/flat MH demonstrated a mean BCVA of 182 
1.76 logMAR at baseline and a mean BCVA of 1.41 logMAR post-operatively (p=0.366). A 183 
postoperatively open/elevated MH demonstrated a mean BCVA of 1.29 logMAR pre-184 
operatively and a mean of 1.98 logMAR post-operatively (p=0.393). A postoperatively closed 185 
MH demonstrated a mean BCVA of 1.43 logMAR pre-operatively and a mean of 1.26 186 
logMAR post-operatively (p=0.651). 187 
Post-operatively 4/20 cases had subretinal fluid (SRF) at 6 months giving a primary retinal 188 
reattachment rate of 80%. Two cases had an open/elevated MH, one case had an open/flat MH 189 
and one further case went on to have a total retinal detachment and reduced BCVA.  190 
Macular retinoschisis 191 
Fifty-three cases of MRS were identified from the retrospective study, which included 27 cases 192 
that underwent surgical management and 26 cases that were managed conservatively. Mean 193 
age in the surgical and conservative groups were 59.4 (range: 36-81) and 63.4 (range 35-99) 194 
years respectively (table 2). Mean baseline BCVA was significantly different between the 195 
surgical group (0.87 logMAR; range: 0.3-1.9) and the conservative management group (0.45 196 
logMAR; range: -0.18-1.8); p=0.002). 197 
All cases that had been managed surgically underwent PPV with 22/27 (81%) having gas 198 
tamponade (table 3) and 2 cases having peripheral laser retinopexy for peripheral retinal breaks 199 
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combined with PPV. The ILM was peeled in 20/27 (74.1%) cases and the most frequently used 200 
endotamponade was SF6 in 9/27 (33.3%) cases. Mean BCVA remained stable in the surgically 201 
managed cases from a baseline of 0.87 logMAR to 0.68 logMAR (range: -0.2-3.0) post-202 
operatively (p=0.183). BCVA deteriorated in 5/27 (18.5%) cases, it was unchanged in 3/27 203 
(11.1%) cases, and improved in 19/27 (70.3%) cases. A total of 12 cases had an improvement 204 
in BCVA of greater than 0.3 logMar units or 2 Snellen lines (Figure 2). The mean follow-up 205 
period was 11.3 months (range: 6 months to 5 years). 206 
Anatomical outcomes showed a persistent MRS in 2/27 (7.4%) cases, partially resolved MRS 207 
in 7/27 (25.9%) cases and completely resolved MRS in 16/27 (59.2%) cases (2 cases 208 
undetermined). Of the cases with a co-existent macular hole, 4/5 (80%) cases were successfully 209 
closed and 1 case remained open and flat.  210 
DISCUSSION 211 
Our present study demonstrates that PPV is the preferred approach for the management of 212 
MHRD and MRS in the UK, bearing in mind that none of the cases reported had previous 213 
failed surgery. Primary macular hole closure rate was 25%, and limited visual improvements 214 
were demonstrated in 60% of eyes. The MRS cases that were managed surgically demonstrated 215 
anatomical improvements in 85% of cases and limited visual improvements in 70% of cases. 216 
One outlier skewed the visual acuity data (figure 2).   217 
 218 
According to the data collected from the current BOSU study, the estimated incidence of 219 
MHRD in the UK is 0.0156 per 100,000 population per year. A total of 19 cases were 220 
identified originally by the BOSU yellow card reporting system, however 9 cases were 221 
excluded on the basis of 2 being over reported, 3 were diagnosed incorrectly, 1 was lost to 222 
follow-up and 3 failed to respond to the questionnaires that were sent out. Our estimate of the 223 
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incidence of MHRD is therefore based on 10 cases reported by 9 vitreoretinal surgeons and 224 
probably represents an underestimation of the true UK incidence of MHRD.  225 
 226 
Traditionally PPV, ERM/ILM peeling with or without gas tamponade have been the primary 227 
treatments for MHRD. All MHRD cases reported in this series are primary cases, thus final 228 
reattachment and closure rates are not available which would explain the 25% reported closure 229 
rates. ILM peeling in addition to peeling of pre-retinal structures for MHRD are generally 230 
considered important to reduce traction and create greater retinal redundancy for the closure of 231 
the macular hole.29-31 However, according to the literature available, macular hole closure rates 232 
using OCT monitoring have generally been low and varied from 10-100% and retinal 233 
reattachment rates have varied from 43-92%.29,32-39 Visual outcomes for MHRD have generally 234 
been disappointing when compared with other forms of surgery for vitreo-macular diseases. 235 
The large ranges for success indicate the complexity of these disorders and the variation in 236 
efficacy of the surgical techniques. Retinal reattachment is usually necessary to assess closure 237 
of the MH, as a persistent large macular detachment is unlikely to coexist with a successfully 238 
closed MH, although persistent shallow subretinal fluid has been reported following surgery 239 
for idiopathic macular hole.32 Therefore closure rates for MH may be more appropriately 240 
quoted in the context of successfully reattached retinae. Clinically, an open but flat MH may be 241 
seen post operatively, which has been attributed to inner retinal shortening and the lack of 242 
retinal redundancy which cannot be compensated for despite peeling of the ILM.40 In our 243 
series, eyes with an open flat macular hole post- operatively had an improvement in visual 244 
acuity but those with an open elevated macular hole post -operatively had worse visual acuity. 245 
Thus, retinal reattachment and a flat but open macular hole may be an acceptable outcome in 246 
some highly myopic eyes with posterior staphyloma. 247 
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Lim et al reviewed 114 subjects with MHRD and reported better visual outcomes in eyes with 248 
retinal reattachment and macular hole closure, indicating the importance of the anatomical 249 
features based on OCT.32 In keeping with our data, visual outcomes were dependant on 250 
macular hole closure although not a statistically significant finding in our report. Furthermore, 251 
greater age at presentation as well as the use of C3F8 tamponade were associated with a greater 252 
likelihood of anatomical success. We found older age to be associated with improved BCVA 253 
post-operatively and C2F6 to have a borderline association with improved BCVA post-254 
operatively, however these findings were not significant when carried through to multivariate 255 
analysis. Larger studies would be required to establish further associations. The presence of 256 
MRS in our study was significantly associated with failure of macular hole closure, in keeping 257 
with a review by Alkabes et al who concluded that eyes with macular holes associated with 258 
foveoschisis required more procedures and had poorer visual outcomes compared with those 259 
without schisis.41 260 
The management of MRS depends on visual symptoms and OCT features as shown in the 261 
present study where eyes that underwent surgical intervention had worse baseline visual acuity 262 
compared to those managed conservatively. Thus, the timing of surgery for myopic MRS is 263 
driven clinically by the visual acuity at presentation. Whilst it is well documented that isolated 264 
MRS is rare and most eyes with myopic MRS remain stable, MRS may be co-existent with 265 
pre-retinal structures, epiretinal membrane, macular hole and macular detachment.7,11,19 MRS 266 
may progress to macular hole and/or retinal detachment in some eyes and the presence of a 267 
foveal detachment is a well documented risk factor for MH formation.19,23,42  268 
In eyes with myopic MRS, better visual outcomes have been associated with better pre-269 
operative vision, shorter axial length and the reattachment of foveal photoreceptors in eyes 270 
with a pre-operative foveal detachment.43 Ikuno et al demonstrated BCVA improvement of 271 
more than 2 lines in 3 out of 8 (37.5%) eyes with MH associated with MRS following PPV 272 
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with ILM peel and gas tamponade.44 In eyes without macular hole, visual acuity improvements 273 
of 2-5 lines and foveal reattachment have been demonstrated in 75-100% of patients following 274 
PPV and gas tamponade with or without ILM peel for MRS. 23,44,45-50 Thus PPV surgery with 275 
peeling of pre-retinal structures and gas tamponade with or without ILM peel for eyes with 276 
isolated myopic MRS is probably the procedure of choice, but visual outcomes are worse when 277 
retinal detachment or macular hole coexist.23 278 
PPV alone does not address the posterior staphyloma, which would suggest some benefit in 279 
posterior scleral reinforcement in the form of episcleral macular buckling (EMB) for patients 280 
with MHRD or MRS. Ando et al in 2007 suggested that the preferred procedure for MHRD in 281 
highly myopic eyes with posterior staphyloma was EMB rather than PPV.51 The authors report 282 
retinal reattachment rates of 93% and 100% after primary and secondary EMB surgery 283 
respectively, compared to 50% after PPV and 86% after redo surgery with an EMB.51 The 284 
visual outcomes were also significantly better in the EMB group compared to the PPV group.51 285 
Other retrospective case series of EMB using varying types of macular buckles have also 286 
demonstrated significant improvements in visual acuity and long term maintenance of macular 287 
hole closure and retinal reattachment.25-29,52-56 In 2011, Devin et al reported the successful use 288 
of a T-shaped scleral buckle which can be threaded along a 2 mm band that is subsequently 289 
secured nasal to the superior and inferior recti; this technique has the added advantages of 290 
avoidance of muscle disinsertion, no use of posterior sutures, and the ability to visually adjust 291 
the height of the buckle.5,28 A more recent study by Mura et al reported on 21 primary or 292 
secondary MHRD cases which either used the T-shaped MB alone or in conjunction with PPV 293 
and reported a final retinal reattachment rate of 100% and a MH closure rate of 90%.28 EMB 294 
have also been used in the management of MRS with a number of studies recommending a 295 
combination of macular buckling and vitrectomy in order to address both inner traction and the 296 
posterior staphyloma.57-59 Recent published data however using a variation on ILM peeling 297 
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have demonstrated macular hole closure rates of 80-100% and retinal reattachment rates of 298 
100% using the inverted ILM flap technique, compared to 36-55% and 55-91% respectively 299 
using standard ILM peeling in cases with MHRD.60,61 300 
 301 
In summary, macular buckling has not been widely adopted in the UK and PPV surgery is 302 
generally considered the primary procedure of choice in eyes with MHRD and MRS where 303 
surgery is indicated. While it appears that a combined approach may yield better anatomic 304 
outcomes in MHRD cases, it remains unclear whether PPV alone would be a reasonable 305 
primary approach leaving EMB to those that fail primary surgery. The inverted ILM flap 306 
technique deserves further study as it may avoid the need for EMB. Limitations of the current 307 
study include the mixed study design and the small sample size. Larger numbers would be 308 
needed to demonstrate a significant change in visual outcomes given the limited scope for 309 
visual acuity improvements. Furthermore, the limited sample of vitreoretinal surgeons 310 
surveyed may not be representative of the whole UK practice. In order to represent current 311 
trends in the management of MRS and MHRD, it was necessary to involve different surgeons. 312 
However, inter-surgeon variation, and the variety of techniques used, may introduce additional 313 
confounding factors. Long-term visual acuity data of MRS cases that were managed 314 
conservatively is lacking thus direct comparison with the surgically managed MRS group and 315 
identifying the optimal time for surgery were not possible.  316 
In conclusion, we present a study of primary PPV for the management of MHRD and MRS. 317 
Macular hole primary closure rates are low, which would suggest the need to consider EMB 318 
either as a primary or secondary procedure, but variations in surgical technique such as the use 319 
of the inverted ILM flap technique deserve further study. Anatomic and visual outcomes of the 320 
management of MRS are similar to those reported in the literature.  321 
 322 
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Titles and legends to figures 533 
Figure 1: A plot of post-operative and pre-operative BCVA (logMAR) in cases of MHRD. The 534 
line of equality represents no change in BCVA with the points below the line indicating an 535 
improvement in BCVA and those above the line indicating a reduction in post-operative 536 
BCVA. 537 
Figure 2: BCVA (logMAR) change in the surgically managed eyes with MRS. The line of 538 
equality represents no change in BCVA with the points below the line indicating an 539 
improvement in BCVA and those above the line indicating a reduction in post-operative 540 
BCVA. One outlier was noted as a result of a total post-operative retinal detachment managed 541 
by vitrectomy and oil and sustained a marked deterioration in the vision.  542 
Table 1: Baseline characteristics and surgical techniques used in the management of MHRD. 
Data missing one case*, two cases** 
  Mean (CI) n=20 
Mean age 63.9 (59.1 to 68.7) 
Mean baseline BCVA (logMAR) 1.60 (1.21 to 1.98) 
Gender n (%) n=20 
Male 6 (30.0) 
Female 14 (70.0) 
Axial length n (%) n=19* 
25.5-30.0mm 10 (52.6) 
>30.0mm 9 (47.4) 
Lens status  n (%) n=18** 
Clear 8 (44.4) 
Cataract 3 (16.7) 
Posterior chamber IOL 7 (38.9) 
Macular pathology n (%) n=19* 
Posterior staphyloma 16 (84.2) 
Non-foveal macular hole 1 (5.3) 
Post-vitreous detachment 10 (52.6) 
Macular retinoschisis 9 (47.4) 
Chorioretinal atrophy 7 (36.8) 
Epiretinal membrane 6 (31.6) 
Choroidal neovascularisation 1 (5.3) 
Surgical procedures n (%) n=19* 
Post-vitreous detachment induced 8 (42.1) 
Epiretinal membrane peeled 8 (42.1) 
Internal limiting membrane peeled 14 (73.7) 
Stain 13 (68.4) 
Laser retinopexy 0 (0.0) 
Explant 0 (0.0) 
Endotamponade n (%) n=20 
None 0 (0.0) 
Air  0 (0.0) 
SF6 1 (5.0) 
C2F6 9 (45.0) 
C3F8 7 (35.0) 
Silicone/heavy oil 3 (15.0) 
Posturing n (%) n=20 
None  3 (15.0) 
<24hrs 0 (0.0) 
1-7 days 11 (55.0) 
>7 days 6(30.0) 
SF6 = Sulphur hexafluoride, C2F6= Hexafluoroethane, C3F8=Perfluoropropane 
Table 2: Macular Retinoschisis (MRS) cases: baseline characteristics. Data missing one case*, more than 
one case** 
 
 
  Total   MRS surgical group   MRS conservative group P-value 
  n=52*   Mean (CI) n=27   Mean (CI) n=25*   
Mean age 52 59.4 (54.65-64.12) 63.4 (57.69-69.16) 0.293 
Mean baseline BCVA 52 0.87 (0.73 to 1.02) 0.45 (0.25 to 0.65) 0.002 
Gender n=53   n (%) n=27   n (%) n=26  
Male 20 12 (30.8) 8 (44.4) 0.305 
Female 33 15 (69.2) 18 (55.6) 
Axial length n=32**    n (%) n=22**   n (%) n=10**   
25.5-30.0mm 23 14 (60.9) 9 (39.1) 0.124 
>30.0mm 9 8 (88.9) 1 (11.1) 
Lens status  n=52*   n (%) n=27   n (%) n=25*    
Clear 30 16 (53.3) 14 (46.6) 0.656 
Cataract 8 3 (37.5) 5 (62.5) 
Posterior chamber IOL 14 8 (57.1) 6 (42.9) 
Macular pathology          
Posterior staphyloma n=52*    n (%) n=27    n (%) n=25*   
No 16 7 (43.8) 9 (56.3) 0.432 
Yes 36 20 (55.5) 16 (44.4) 
Non-foveal macular hole n=52*  n (%) n=27 n (%) n=25* 
No 49 24 (49.0) 25 (51.0) 0.086
Yes 3 3 (100.0) 0 (0.0) 
Post-vitreous detachment n=52*    n (%) n=27   n (%) n=25*   
No 30 15 (50.0) 15 (50.0) 0.746 
Yes 22 12 (54.6) 10 (45.5) 
Chorioretinal atrophy n=52*    n (%) n=27   n (%) n=25*   
No 35 15 (42.9) 20 (57.1) 0.060 
Yes 17 12 (70.6) 5 (29.4) 
Epiretinal membrane n=52*    n (%) n=27    n (%) n=25*   
No 35 15 (42.9) 20 (57.1) 0.060 
Yes 17 12 (70.6) 5 (29.4) 
Choroidal neovascularisation n=52*    n (%) n=27    n (%) n=25*   
No 51 27 (52.9) 24 (47.1) 0.294 
Yes 1 0 (0.0) 1 (100.0) 
Macular hole  n=53 n (%) n=27 n (%) n=26 
No 48 22 (46.9) 26 (53.1) 0.041 
Yes 5   5 (100.0)   0 (0.0)   


